PubMed Health⌕ Search

PubMed · 10089165

Time Correlations in Fluid Transport Obtained by Sequential Rephasing Gradient Pulses.

Abstract

We present a basic experiment by which the evolution of the displacement probability density (propagator) of static or flowing fluid in N successive time intervals is obtained by single labeling, coupled with multiple rephasing events during the course of a pulsed field-gradient sequence. We term this type of sequence SERPENT: SEquential Rephasing by Pulsed field-gradients Encoding N Time-intervals. Realizations of the SERPENT experiment for the case N = 2 which include spin echo, stimulated echo, and Carr-Purcell pulse sequences are suggested. They have in common a spatial spin-labeling of the initial magnetization by a gradient of area q0, followed by successive rephasing via gradients q1 and q2 at times t = Delta1 and t = Delta2, respectively, where q0 + q1 + q2 = 0. A two-dimensional Fourier transform with respect to q1 and q2 gives directly the joint probability density W2(R1, Delta1; R2, Delta2) for displacements R1 and R2 in times Delta1 and Delta2, respectively. q1 and q2 may be in arbitrary directions. Assuming R1 ||R2, the correlation coefficient rhoR1,R2 then reflects the time-history of the fluctuating velocities. The behavior of the cross moment can be obtained from either a full two-dimensional or a set of one-dimensional SERPENT measurements. Experimental results are presented for water flowing through a bed of packed glass beads. While Delta1 is appropriately chosen to sample the short-time velocity field within the system, increasing Delta2 clearly shows the loss of correlation when the average fluid element displacement exceeds the bead diameter. Copyright 1999 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Stapf, RA Damion, KJ Packer. 1999. Time Correlations in Fluid Transport Obtained by Sequential Rephasing Gradient Pulses.. https://doi.org/10.1006/jmre.1998.1685

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗